Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 5:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 707 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: IT Injection Clear all
Completed Phase 4 Interventional Results available

Exparel for Total Shoulder Arthroplasty

NCT04364867
View directory record Official record
Conditions
Total Shoulder Arthroplasty
Interventions
Exparel, Pain Pump
Drug
Lead sponsor
Norton Healthcare
Other
Eligibility
18 Years to 70 Years
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 1 Interventional

Poly-ICLC (Hiltonol®) Vaccine In Malignant Pleural Mesothelioma

NCT04525859
View directory record Official record
Conditions
Malignant Pleural Mesothelioma
Interventions
Safety, Expansion Cohort
Biological
Lead sponsor
Oncovir, Inc.
Industry
Eligibility
Not listed
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Oct 22, 2026, 5:25 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Contraceptive Hormones, Immunity, and Microbiome Evaluation

NCT03660046
View directory record Official record
Conditions
Hormonal Contraception
Interventions
Depot medroxyprogesterone acetate (DMPA), Etonogestrel implant (Eng-Implant), Levonorgestrel IUD (Lng-IUD)
Drug
Lead sponsor
Emory University
Other
Eligibility
Up to 45 Years · Female only
Enrollment
155 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2023
U.S. locations
3
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL)

NCT00098839
View directory record Official record
Conditions
Recurrent Childhood Acute Lymphoblastic Leukemia
Interventions
L-asparaginase, doxorubicin hydrochloride, therapeutic hydrocortisone, vincristine sulfate, epratuzumab, cytarabine, prednisone, pegaspargase, dexrazoxane hydrochloride, methotrexate, etoposide, cyclophosphamide, leucovorin calcium, filgrastim
Drug · Biological
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Years to 31 Years
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
42
States / cities
Birmingham, Alabama • Loma Linda, California • Long Beach, California + 36 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 2 Interventional

Phase II Study of Tailored-Dose Docetaxel in Metastatic Breast Cancer

NCT00148070
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Docetaxel, Erythromycin Breath Test (ERMBT)
Drug · Procedure
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2006
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 5, 2012 · Synced Oct 22, 2026, 5:25 AM EDT
Active, not recruiting Not applicable Interventional

Testing a Brief Reassurance Message Before a Musculoskeletal Clinic Visit

NCT07330492
View directory record Official record
Conditions
Any Non-traumatic Musculoskeletal Condition
Interventions
Nudge intervention
Behavioral
Lead sponsor
University of Texas at Austin
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 1 Interventional

Ph. 1, Evaluation of Safety, Tolerability, PK, Anti-tumor Activity of STP707 IV in Subjects With Solid Tumors

NCT05037149
View directory record Official record
Conditions
Solid Tumor
Interventions
STP707
Drug
Lead sponsor
Sirnaomics
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Phoenix, Arizona • Los Angeles, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

ESP vs QL for Total Abdominal Hysterectomy

NCT04074226
View directory record Official record
Conditions
Postoperative Pain
Interventions
Erector Spinae Plane block, Quadratus Lumborum Block
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 4, 2023 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 1 Interventional

Natural Killer Cells and Bortezomib to Treat Cancer

NCT00720785
View directory record Official record
Conditions
Chronic Myeloid Leukemia (CML), Pancreatic Ca, Colon/Rectal Ca, Multiple Myeloma, Carcinoma, Non-Small -Cell Lung
Interventions
Bortezomib, NK cells
Drug · Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Enrolling by invitation Not applicable Interventional Accepts healthy volunteers

Autoimmune Basis for Postural Tachycardia Syndrome

NCT02725060
View directory record Official record
Conditions
Postural Orthostatic Tachycardia Syndrome, Postural Tachycardia Syndrome, Tachycardia, Arrhythmias, Cardiac, Autonomic Nervous System Diseases, Orthostatic Intolerance, Cardiovascular Diseases, Primary Dysautonomias
Interventions
phenylephrine, isoproterenol, 25 micro-Ci of radiation, Posture study with blood samples, 24-hour heart rhythm and blood pressure monitoring, Quantitative Axonal Sudomotor Reflex Testing, Autonomic function tests, Rebreathing test, Assessment of splanchnic capacitance, microneurography
Drug · Radiation · Procedure + 1 more
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 50 Years
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2026
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

Study to Assess the Efficacy and Long-term Safety of Dupilumab (REGN668/SAR231893) in Adult Participants With Moderate-to-Severe Atopic Dermatitis

NCT02260986
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Dupilumab, Placebo (for Dupilumab), Topical Corticosteroid (TCS)
Drug · Other
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
740 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
50
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 47 more
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 2 Interventional

A Study of CT-868 in Type 1 Diabetes Mellitus

NCT06062069
View directory record Official record
Conditions
Overweight, Obese, Type 1 Diabetes Mellitus
Interventions
CT-868, CT-868 Pen Injector, CT-868 Pen Injector, Placebo
Drug · Device
Lead sponsor
Carmot Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
22
States / cities
Concord, California • Escondido, California • Aurora, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 17, 2025 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform

NCT02431702
View directory record Official record
Conditions
Schizophrenia, Psychotic Disorders
Interventions
Aripiprazole, Haloperidol, Olanzapine, Oral Paliperidone ER, Perphenazine, Quetiapine, Oral Risperidone, Paliperidone Palmitate Injection (PP1M), Paliperidone Palmitate Injection (PP3M)
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 35 Years
Enrollment
337 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
34
States / cities
Little Rock, Arkansas • Garden Grove, California • Lemon Grove, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 2 Interventional

Treatment for Advanced B-Cell Lymphoma

NCT01859819
View directory record Official record
Conditions
Diffuse Large Cell Lymphoma, Burkitt's Lymphoma, High Grade B-cell Lymphoma
Interventions
Rituximab, IT Cytarabine
Drug
Lead sponsor
New York Medical College
Other
Eligibility
3 Years to 31 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
5
States / cities
Buffalo, New York • Valhalla, New York • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2022 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 4 Interventional Results available

High Dose Risperidone Consta for Patients With Schizophrenia With Poor Response to Risperidone

NCT00539071
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
long-acting injectable risperidone, long acting injectable risperidone, Conventional Dose Group, long acting injectable risperidone, High Dose Group
Drug
Lead sponsor
Northwestern University
Other
Eligibility
18 Years to 65 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 22, 2026, 5:25 AM EDT
Recruiting Early Phase 1 Interventional

Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Bone Marrow or Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies

NCT06398457
View directory record Official record
Conditions
Hematologic Malignancy, Bone Marrow Transplant Rejection, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Acute Lymphoblastic Leukemia (ALL), Adult, Multiple Myeloma, Aplastic Anemia, Lymphoma, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Chronic Myeloid Leukemia, Myelofibrosis
Interventions
Darzalex Faspro (Daratumumab and hyaluronidase-fihj), JH-DSA Semi-Quant Screen and Response Score
Drug · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Brain Stimulation-aided Stroke Rehabilitation: Neural Mechanisms of Recovery

NCT01539096
View directory record Official record
Conditions
Stroke
Interventions
tDCS: noninvasive brain stimulation, Constraint induced movement therapy (CIMT), Sham tDCS: placebo noninvasive brain stimulation
Procedure · Behavioral
Lead sponsor
The Cleveland Clinic
Other
Eligibility
21 Years and older
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2019
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 16, 2020 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Promoting Flu Vaccination Through a Mobile Wellness Program

NCT02908893
View directory record Official record
Conditions
Not Condition-specific
Interventions
In-app and push notification mobile messages
Behavioral
Lead sponsor
Evidation Health
Industry
Eligibility
18 Years to 65 Years
Enrollment
50,286 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Santa Barbara, California
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 3 Interventional Results available

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)

NCT03160885
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
40
States / cities
Hot Springs, Arkansas • Encinitas, California • Fullerton, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Early Phase 1 Interventional

Adrenocorticotropic Hormone (ACTH) for Post-op Inflammation in Proliferative Vitreoretinopathy (PVR)

NCT03727776
View directory record Official record
Conditions
Proliferative Vitreoretinopathy
Interventions
Adrenocorticotropic Hormone
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 8, 2023 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Not applicable Interventional Results available

Computed Tomography Versus Standard 2D Mammography Versus 3D Tomosynthesis

NCT01852032
View directory record Official record
Conditions
Breast Cancer
Interventions
Tomosynthesis Breast Scanning, Breast CT Scanning
Radiation
Lead sponsor
University of California, Davis
Other
Eligibility
35 Years and older · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2018 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Phase 4 Interventional Results available

Lumbar Plexus vs Quadratus Lumborum Block in Post-operative Pain Following Total Hip Replacement

NCT03801265
View directory record Official record
Conditions
Hip Osteoarthritis
Interventions
Lumbar plexus block, Quadratus lumborum type 3 block, Ropivacaine injection
Procedure · Drug
Lead sponsor
Sharad Khetarpal
Other
Eligibility
18 Years to 90 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 15, 2021 · Synced Oct 22, 2026, 5:25 AM EDT
Completed Early Phase 1 Interventional

Triamcinolone Acetonide Injections in Mild-to-moderate Chronic Plaque Psoriasis With a Novel Needle-free Drug-delivery System

NCT04410237
View directory record Official record
Conditions
Psoriasis
Interventions
Med-Jet, Traditional Syringe
Device · Other
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 18, 2023 · Synced Oct 22, 2026, 5:25 AM EDT
Recruiting Early Phase 1 Interventional

Window Trial of Intratumoral (IT) Neoadjuvant Fluorescently Labelled Nivolumab (nivo800) in Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT07741565
View directory record Official record
Conditions
HNSCC, SCC - Squamous Cell Carcinoma, Oral Cancer
Interventions
Nivolumab-IRDye800
Drug
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 22, 2026, 5:25 AM EDT